Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Congenital Factor XIII Deficiency
2009-010722-19Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Factor XIII (human) in congenital factor XIII deficiency, sponsored by CSL Behring. Primary endpoints: Frequency of bleeding episodes during prophylactic treatment, Severity of bleeding episodes during prophylactic treatment and 4 more. Started Aug 2009; status: completed.
02
Drugs
Factor XIII (human)
03
Conditions
congenital factor XIII deficiency
Beyond the preview
Go deeper on 2009-010722-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010722-19.